12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Company News  |  Deals

Addex, Merck deal

Addex disclosed in its 2Q11 earnings that Merck terminated a 2008 deal and returned rights to schizophrenia candidate ADX63365. The...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >